tradingkey.logo
tradingkey.logo
Search

Jupiter Neurosciences Inc

JUNS
Add to Watchlist
0.223USD
+0.008+3.72%
Close 07/02, 13:00ETQuotes delayed by 15 min
8.09MMarket Cap
LossP/E TTM

More Details of Jupiter Neurosciences Inc Company

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.

Jupiter Neurosciences Inc Info

Ticker SymbolJUNS
Company nameJupiter Neurosciences Inc
IPO dateDec 03, 2024
CEORosen (Christer)
Number of employees4
Security typeOrdinary Share
Fiscal year-endDec 03
Address1001 North US HWY 1, Suite 504
CityPALM BEACH GARDENS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33477
Phone15614066154
Websitehttps://jupiterneurosciences.com/
Ticker SymbolJUNS
IPO dateDec 03, 2024
CEORosen (Christer)

Company Executives of Jupiter Neurosciences Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Christer Rosen
Mr. Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
10.58M
-4.70%
Mr. Alexander Gustaf Erik Rosen
Mr. Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Co-Founder, Chief Administrative Officer
452.86K
-36.34%
Ms. Allison W. Brady
Ms. Allison W. Brady
Independent Director
Independent Director
21.75K
-358.62%
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Independent Director
Independent Director
10.77K
-796.68%
Ms. Alison D Silva
Ms. Alison D Silva
President, Chief Business Officer, Director
President, Chief Business Officer, Director
2.55K
-4322.63%
Dr. Marshall A Hayward, Ph.D.
Dr. Marshall A Hayward, Ph.D.
Co-Founder, Chief Scientific Officer, Director
Co-Founder, Chief Scientific Officer, Director
--
--
Mr. Nicholas H. Hemmerly
Mr. Nicholas H. Hemmerly
Independent Director
Independent Director
--
-100.00%
Ms. Julie Kampf
Ms. Julie Kampf
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Christer Rosen
Mr. Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
10.58M
-4.70%
Mr. Alexander Gustaf Erik Rosen
Mr. Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Co-Founder, Chief Administrative Officer
452.86K
-36.34%
Ms. Allison W. Brady
Ms. Allison W. Brady
Independent Director
Independent Director
21.75K
-358.62%
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Independent Director
Independent Director
10.77K
-796.68%
Ms. Alison D Silva
Ms. Alison D Silva
President, Chief Business Officer, Director
President, Chief Business Officer, Director
2.55K
-4322.63%
Dr. Marshall A Hayward, Ph.D.
Dr. Marshall A Hayward, Ph.D.
Co-Founder, Chief Scientific Officer, Director
Co-Founder, Chief Scientific Officer, Director
--
--

FAQs

Who are the top five shareholders of Jupiter Neurosciences Inc?

The top five shareholders of Jupiter Neurosciences Inc are: Mr. Christer Rosen

How many institutions hold shares of Jupiter Neurosciences Inc (JUNS)?

As of 2026Q1, 21 institutions hold shares of Jupiter Neurosciences Inc, with a combined market value of approximately 2.06M, accounting for 5.68% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1545404.00.